glycopyrronium + indacaterol acetate + mometasone at a glance
Medicine class
Inhaled corticosteroid plus long-acting beta₂ agonist and long-acting muscarinic antagonist.
Licensed use
Maintenance treatment of selected adults with inadequately controlled asthma and a recent exacerbation.
Form
Dry-powder capsules used only with the supplied Breezhaler inhaler; do not swallow them.
Sudden symptoms
This is not a reliever inhaler and must not be used for an acute asthma attack.
What is glycopyrronium + indacaterol acetate + mometasone used for?
The selected product is licensed for maintenance treatment of selected adults with inadequately controlled asthma and a recent exacerbation.
It is not licensed as a reliever or for acute bronchospasm.
The selected product does not have a UK COPD indication.
How does glycopyrronium + indacaterol acetate + mometasone work?
Indacaterol and glycopyrronium relax the airways through complementary actions. Mometasone reduces airway inflammation.
How to take glycopyrronium + indacaterol acetate + mometasone
Use exactly as prescribed and follow the pack instructions. Correct technique is important.
Remove a capsule from its blister immediately before use, using dry hands.
Place it in the supplied inhaler's capsule chamber, never the mouthpiece, and pierce it once.
Breathe out away from the device, then inhale quickly and deeply through the mouthpiece.
If powder remains, repeat the inhalation steps with the same capsule.
Discard the empty capsule, rinse your mouth with water and spit it out.
Keep the inhaler dry. Clean the mouthpiece with a dry, lint-free cloth and never wash it with water.
glycopyrronium + indacaterol acetate + mometasone side effects
Common or expected effects
- Sore throat, runny nose or upper respiratory infection
- Oral thrush, throat discomfort or hoarse voice
- Headache
- Cough
- Fast heartbeat
- Muscle, bone or joint pain; muscle spasms
- Urinary tract infection
- Fever or gastroenteritis
Get urgent medical advice
- Sudden chest tightness, wheezing or breathlessness immediately after inhalation
- Difficulty breathing or swallowing, facial or tongue swelling, hives or widespread rash
- Eye pain or redness with blurred vision, coloured images or haloes
- Rapid or progressive worsening of asthma symptoms
glycopyrronium + indacaterol acetate + mometasone in pregnancy
Product-specific pregnancy data are insufficient. The prescriber should weigh the expected benefit against possible fetal risk. Good asthma control remains important: do not stop prescribed treatment without advice, and arrange review if pregnant, planning pregnancy or experiencing worsening symptoms. Evidence concerning inhaled corticosteroids is generally reassuring but does not establish the safety of the complete combination.
glycopyrronium + indacaterol acetate + mometasone while breastfeeding
There are no adequate human milk data for the complete combination. Inhaled mometasone is expected to produce negligible milk exposure, but evidence for the other components is limited. The prescriber should balance asthma control, breastfeeding benefits and theoretical infant risk. Specialist advice is particularly useful for a premature or unwell infant.
glycopyrronium + indacaterol acetate + mometasone interactions
Ask a prescriber or pharmacist to review all medicines, including inhalers and eye drops. Important examples include:
Other long-acting beta₂ agonists or long-acting muscarinic antagonists
Concurrent use is not recommended because overlapping actions may increase adverse effects.
Beta blockers, including propranolol and timolol eye drops
They can oppose indacaterol and may provoke bronchospasm.
Tricyclic antidepressants, monoamine oxidase inhibitors and QT-prolonging medicines
They may increase cardiac rhythm risks associated with beta₂-agonist effects.
Common questions about glycopyrronium + indacaterol acetate + mometasone
Answers are fully visible for fast scanning and source review.
Is this a reliever inhaler?
No. It is a maintenance controller and should not be used for sudden wheeze or an acute asthma attack; use the reliever specified in the asthma action plan.
Is it licensed for COPD?
Not in the selected UK product. Its licensed indication is maintenance treatment of selected adults with asthma.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.